Atricure Stock Price, News & Analysis

AtriCure, a leader in innovative surgical treatments for atrial fibrillation (Afib), announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The company’s management will conduct a fireside chat on April 17, 2023, at 1:30 PM EST. Interested parties can access a live audio webcast in the ‘Investors’ section on AtriCure's website. AtriCure focuses on the development of technologies for Afib treatment and LAA management, with over 37 million individuals affected by Afib globally. The firm’s devices, including the Isolator® Synergy™ Ablation System and the AtriClip® LAA Exclusion System, are widely used by healthcare professionals.

AtriCure, Inc. (Nasdaq: ATRC) reported a 20.4% increase in worldwide revenue for 2022, totaling $330.4 million. U.S. revenue reached $277.2 million, up 21.0%, while international sales rose 17.7% to $53.2 million. The fourth quarter revenue was $88.0 million, marking a 20.2% increase year-over-year. Despite strong growth, the company reported a loss from operations of $42.7 million for 2022, alongside a net loss per share of $1.02. Looking ahead, 2023 revenue is projected between $380 million and $387 million, reflecting growth of 15% to 17%. The company aims for adjusted EBITDA to break even in 2023.

AtriCure, Inc. (NASDAQ: ATRC) announced its participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 15, 2023, at 8:00 am EST. The conference will feature a presentation by AtriCure's management team. Interested investors can access the live audio webcast through the 'Investors' section of AtriCure’s website. AtriCure is known for its innovative surgical treatments targeting atrial fibrillation (Afib) and related conditions. The company provides several unique products, including the Isolator® Synergy™ Ablation System and AtriClip® LAA management devices.

AtriCure, Inc. has initiated the LeAAPS clinical trial to assess the safety and effectiveness of its AtriClip^® LAA Exclusion System for stroke prevention in cardiac surgery patients. The trial, involving up to 6,500 patients across 250 centers worldwide, is notable for being the largest randomized trial in surgical LAA exclusion. The goal is to establish new treatment protocols for patients at risk of ischemic stroke. The AtriClip System is recognized as a leading device in LAA management. CEO Michael Carrel emphasized the trial's potential to enhance patient outcomes and expand market opportunities.

AtriCure, Inc. (NASDAQ: ATRC) announced its fourth quarter and full year 2022 financial results will be released on February 21, 2023. An audio webcast and investor meetings are scheduled for the same date and also on February 14, 2023, at the BTIG MedTech Conference in Snowbird, Utah. AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions, with FDA-approved technologies such as the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System. These advancements cater to over 37 million Afib patients globally, cementing AtriCure's position in the medtech industry.

AtriCure, Inc. (Nasdaq: ATRC) announced preliminary financial results for Q4 2022 and provided 2023 guidance. Q4 revenue is expected at $88.0 million, a 20% increase from Q4 2021. Full year 2022 revenue reached $330.4 million, also reflecting 20% growth. Adjusted EBITDA is projected at a $4 million loss, while adjusted loss per share is estimated between $1.10 and $1.12. For 2023, revenue guidance is set at $380 million to $387 million, indicating a 15%-17% growth.

AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation and related conditions, announced participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 7:30 am PST. The presentation can be accessed through the company’s Investors webpage. AtriCure is renowned for its innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® devices, which are used worldwide for the management of Afib, affecting over 37 million people globally.

AtriCure, Inc. (NASDAQ: ATRC) has announced its participation in the 34th Annual Piper Sandler Healthcare Conference. The company is set to present on November 30, 2022, at 9:30 a.m. Eastern Time. A live audio webcast can be accessed via the Investors section on AtriCure's website. AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions, providing innovative technologies including the FDA-approved Isolator® Synergy™ Ablation System and AtriClip® devices for left atrial appendage management.

AtriCure, Inc. (Nasdaq: ATRC) reported third quarter 2022 revenue of $83.2 million, an 18.1% increase from the previous year. U.S. revenue rose to $69.8 million, up 21.3%, driven by strong sales of the cryoSPHERE® probe and AtriClip® Flex·V® device. International revenue grew by 4.2% to $13.4 million. However, the company posted a loss from operations of $10.7 million, and adjusted EBITDA was negative at $0.7 million. Full-year guidance predicts revenue between $328 million and $333 million with an adjusted loss per share of $1.10 to $1.12.